Application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of preparation for relieving obesity

Abstract

The invention relates to an application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for relieving obesity. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The brand new application of the BLa80 strain of the animal bifidobacterium subsp. Lactis is developed, that is, the BLa80 strain is used for improving obesity, specifically, the BLa80 strain can effectively control the weight gain of obese mice and reduce the obesity index; fat accumulation, liver injury and in-vivo inflammation caused by obesity are improved; the intestinal flora structure of an obese organism can be improved, the abundance of beneficial flora in the intestinal tract is increased, and the abundance of conditioned pathogenic bacteria is reduced.

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms and relates to a new use of animal Bifidobacterium lactis subspecies BLa80, and particularly relates to an application of animal Bifidobacterium lactis subspecies BLa80 in preparing a preparation for alleviating obesity. Background Art

[0002] Obesity is caused by a complex interaction of genetic and environmental factors and is also considered to be the result of a long-term imbalance between energy intake and expenditure. With the dramatic changes in dietary structure in recent years, the continued intake of high-calorie foods high in fat or carbohydrates, coupled with a sedentary lifestyle, is the most common factor contributing to the global obesity epidemic. Obesity is a chronic metabolic disease characterized by excessive accumulation of body fat, often accompanied by imbalances in energy metabolism and multiple health risks. It is associated with a variety of diseases such as atherosclerosis, type 2 diabetes, stroke, and hypertension. Traditional interventions (such as diet control, medication, and surgery) have some effectiveness, but they have limitations such as high side effects and a tendency to rebound.

[0003] In recent years, many research results have confirmed that probiotics have become a hot strategy for improving obesity by regulating intestinal flora to promote metabolism. Obese people may have characteristic changes in intestinal flora diversity and disordered flora structure. This flora imbalance can affect host metabolism through multiple mechanisms: (1) Impaired energy metabolism regulation: reduced short-chain fatty acids produced by bacterial fermentation of dietary fiber, leading to weakened liver gluconeogenesis inhibition and increased adipose tissue lipolysis; (2) Intestinal barrier damage: downregulation of tight junction protein expression, increased endotoxin translocation, and induction of chronic low-grade inflammation; (3) Bile acid metabolism disorder: affecting the farnesoid X receptor and G protein-coupled bile acid receptor 1 signaling pathways, interfering with glucose and lipid metabolism balance; (4) Dysfunction of the brain-gut axis: affecting the secretion of metabolic regulatory peptides by enteroendocrine cells, leading to abnormal appetite regulation and excessive energy intake.

[0004] Bifidobacterium animalis subsp. lactis is a Gram-positive bacillus found in the human intestine. It helps maintain a balanced intestinal flora, reducing harmful bacteria and increasing beneficial bacteria, improving intestinal health and promoting metabolism. Bifidobacterium animalis subsp. lactis in the human intestine plays a vital role in human health. Currently, there are still few Bifidobacterium animalis subsp. lactis products that can effectively treat obesity. Therefore, identifying and developing more intervention strategies for Bifidobacterium animalis subsp. lactis is of great significance. Summary of the Invention

[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a new use of animal Bifidobacterium lactis subspecies BLa80, and specifically to the use of animal Bifidobacterium lactis subspecies BLa80 in the preparation of a preparation for alleviating obesity.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a use of Bifidobacterium animalis subspecies lactis BLa80 in the preparation of a preparation for alleviating obesity;

[0008] The Bifidobacterium animalis subsp. lactis BLa80 is a strain of Bifidobacterium animalis subsp. lactis BLa80 with a preservation number of CGMCC No. 22547.

[0009] The present invention has developed a new use for the animal Bifidobacterium lactis subsp. lactis BLa80 strain, namely, its use for improving obesity. Specifically, the BLa80 strain can effectively control the weight gain of obese mice and reduce the obesity index; improve fat accumulation, liver damage and inflammation in the body caused by obesity; and can also improve the intestinal flora structure of obese organisms, increase the abundance of beneficial intestinal flora, and reduce the abundance of opportunistic pathogens.

[0010] Preferably, the number of viable bacteria in the preparation is not less than 1×10 8 CFU / mL or 1×10 8 CFU / g, for example 1×10 8 CFU / mL (CFU / g), 5×10 8 CFU / mL (CFU / g), 1×10 9 CFU / mL (CFU / g), 5×10 9 CFU / mL (CFU / g), 1×10 10 CFU / mL (CFU / g), 1×10 11 CFU / mL (CFU / g), etc.

[0011] Preferably, the dosage form of the preparation includes solution, powder, tablet or capsule.

[0012] Preferably, the preparation further contains excipients; the excipients include any one or a combination of at least two of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers.

[0013] Preferably, the preparation further contains prebiotics, which include human milk oligosaccharides, seaweed oligosaccharides and collagen peptides.

[0014] The present invention also creatively discovered that further adding prebiotics consisting of human milk oligosaccharides, seaweed oligosaccharides and collagen peptides to the above-mentioned probiotic preparation can further enhance the effect of the probiotic preparation in alleviating obesity, and the simultaneous use of the three prebiotics is more effective in achieving the above-mentioned effects than the use of a single prebiotic or two prebiotics, indicating that the three prebiotics synergistically enhance the above-mentioned effects.

[0015] Preferably, the mass ratio of human milk oligosaccharides, seaweed oligosaccharides and collagen peptides is (2-5):(2-5):1, for example, 2:2:1, 3:2:1, 4:2:1, 5:2:1, 2:3:1, 3:3:1, 4:3:1, 5:3:1, 2:4:1, 3:4:1, 4:4:1, 5:4:1, 2:5:1, 3:5:1, 4:5:1, 5:5:1, etc.

[0016] Based on the potential mutual promotion effect of the three prebiotics in improving the effect of alleviating obesity, the effect is better when they meet the above-mentioned specific mass ratio relationship.

[0017] Preferably, the human milk oligosaccharide is selected from lactose-N-neotetraose and / or 2'-fucosyllactose, more preferably a combination of lactose-N-neotetraose and 2'-fucosyllactose.

[0018] Preferably, the seaweed oligosaccharide is selected from fucoidan and / or chitosan oligosaccharide.

[0019] Preferably, the collagen peptide is selected from bovine collagen peptide and / or fish collagen peptide.

[0020] In a second aspect, the present invention provides a probiotic composition for alleviating obesity, the probiotic composition comprising probiotics and prebiotics; the probiotics are Bifidobacterium animalis subspecies lactis BLa80, and the prebiotics comprise human milk oligosaccharides, seaweed oligosaccharides, and collagen peptides;

[0021] The Bifidobacterium animalis subsp. lactis BLa80 is a strain of Bifidobacterium animalis subsp. lactis BLa80 with a preservation number of CGMCC No. 22547.

[0022] Preferably, the ratio of probiotics to prebiotics is not less than 1×10 7 CFU, for example 1 × 10 7 CFU, 5×10 7 CFU, 1×10 8 CFU, 5×10 8 CFU, 1×10 9 CFU, 5×10 9 CFU, 1×1010 CFU, 1×10 11 CFU, etc.

[0023] Preferably, the mass ratio of human milk oligosaccharides, seaweed oligosaccharides and collagen peptides is (2-5):(2-5):1, for example, 2:2:1, 3:2:1, 4:2:1, 5:2:1, 2:3:1, 3:3:1, 4:3:1, 5:3:1, 2:4:1, 3:4:1, 4:4:1, 5:4:1, 2:5:1, 3:5:1, 4:5:1, 5:5:1, etc.

[0024] Preferably, the human milk oligosaccharide is selected from lactose-N-neotetraose and / or 2'-fucosyllactose, more preferably a combination of lactose-N-neotetraose and 2'-fucosyllactose.

[0025] Preferably, the seaweed oligosaccharide is selected from fucoidan and / or chitosan oligosaccharide.

[0026] Preferably, the collagen peptide is selected from bovine collagen peptide and / or fish collagen peptide.

[0027] In a third aspect, the present invention provides use of the probiotic composition of the second aspect in preparing a product having any one or at least two of the following effects:

[0028] 1) Reduce obesity index; 2) Improve fat accumulation caused by obesity; 3) Liver damage caused by obesity; 4) Inflammation in the body caused by obesity; 5) Improve the intestinal flora structure of obese individuals, increase the abundance of beneficial intestinal flora, and reduce the abundance of opportunistic pathogens.

[0029] All other point values not specifically listed in the numerical ranges involved in the present invention are within the protection scope of the present invention. Considering the length of the article and the brevity of the explanation, they will not be described in detail here.

[0030] Compared with the prior art, the present invention has the following beneficial effects:

[0031] The present invention has developed a new use for the animal Bifidobacterium lactis subsp. lactis BLa80 strain, namely, its use for improving obesity. Specifically, the BLa80 strain can effectively control the weight gain of obese mice and reduce the obesity index; improve fat accumulation, liver damage and inflammation in the body caused by obesity; and can also improve the intestinal flora structure of obese organisms, increase the abundance of beneficial intestinal flora, and reduce the abundance of opportunistic pathogens.

[0032] Furthermore, a probiotic composition for alleviating obesity was developed, the active components of which include probiotics and prebiotics; the probiotic is Bifidobacterium animalis subspecies lactis BLa80, and the prebiotics include human milk oligosaccharides, seaweed oligosaccharides and collagen peptides; the study found that the combination of the above-mentioned prebiotics with BLa80 can further enhance the effect of the probiotic preparation in alleviating obesity, and the three prebiotics synergistically enhance the above-mentioned effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 is the statistical result graph of the weight values of mice in each group;

[0034] Figure 2 is the statistical result graph of obesity index of mice in each group;

[0035] Figure 3 is the statistical result graph of liver index of mice in each group;

[0036] Figure 4 This is the statistical result of epididymal white fat index of mice in each group;

[0037] Figure 5 This is the statistical result of the inguinal white fat index of each group of mice;

[0038] Figure 6 This is the statistical result of scapular brown fat index of mice in each group;

[0039] Figure 7 This is the statistical result of alanine aminotransferase levels in the liver of mice in each group;

[0040] Figure 8 This is the statistical result of aspartate aminotransferase levels in the liver of mice in each group;

[0041] Figure 9 This is a statistical graph of LPS levels in the livers of mice in each group;

[0042] Figure 10 are the histopathological sections of the liver tissues of mice in each group;

[0043] Figure 11 is the pathological section of epididymal white adipose tissue of mice in each group;

[0044] Figure 12 are the pathological sections of inguinal white adipose tissue of mice in each group;

[0045] Figure 13 are the pathological sections of brown adipose tissue of the scapula of mice in each group;

[0046] Figure 14 is the NMDS analysis result of the intestinal flora of mice in each group;

[0047] Figure 15 This is the evolutionary branch diagram of the LEfSe analysis of the intestinal flora of each group of mice;

[0048] Figure 16 This is the statistical result of the relative abundance of intestinal flora in each group of mice;

[0049] The BLa80 strain involved in the present invention is classified and named as Bifidobacterium animalis subsp. lactis, the preservation time is May 17, 2021, the preservation number is CGMCC No. 22547, the preservation unit is the General Microbiology Center of the China Culture Collection Administration, and the preservation address is No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing. DETAILED DESCRIPTION

[0050] The technical solution of the present invention is further described below by way of specific embodiments. It should be understood by those skilled in the art that the embodiments are merely to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0051] The BLa80 strain involved below is classified and named as Bifidobacterium animalis subsp. lactis, the preservation date is May 17, 2021, and the preservation number is CGMCC No. 22547.

[0052] The preparation method of the BLa80 bacterial suspension involved in the following experiment is as follows: the BLa80 strain is inoculated into L-MRS liquid culture medium, cultured at 37°C for 18 hours for activation, and activated twice continuously to obtain an activated liquid; the activated liquid is inoculated into L-MRS liquid culture medium at an inoculum rate of 3% (v / v), and cultured at 37°C for 15 hours to obtain a bacterial liquid; the bacterial liquid is centrifuged at 8000 rpm for 1 minute, the supernatant is discarded to obtain bacterial cells, the bacterial cells are resuspended in physiological saline and diluted as needed to obtain a BLa80 bacterial suspension.

[0053] L-MRS medium: peptone 10 g / L, beef extract 10 g / L, glucose 20 g / L, sodium acetate 2 g / L, yeast extract 5 g / L, diammonium hydrogen citrate 2 g / L, dipotassium hydrogen phosphate 2 g / L, magnesium sulfate heptahydrate 0.58 g / L, manganese sulfate 0.25 g / L, Tween 80 1 mL / L, cysteine hydrochloride 0.1 g / L.

[0054] The lactose-N-neotetraose involved in the following experiments is the product purchased from Maclean Company with model number 13007-32-4; the brown algae oligosaccharide is the product purchased from Qingdao Bozhi Huili Biotechnology Co., Ltd.; the fish collagen peptide is the product purchased from Guangzhou Huayu Biotechnology Co., Ltd.; the 2'-fucosyllactose is the product purchased from Maclean Company with model number 41263-94-9; the chitosan oligosaccharide is the product purchased from Maclean Company with model number 148411-57-8; and the bovine collagen peptide is the product purchased from Guangzhou Huayu Biotechnology Co., Ltd.

[0055] Example

[0056] This example explores the ability of probiotics to improve symptoms in obese mice:

[0057] (1) Experimental Animals: Healthy male C57BL / 6j mice (5–6 weeks; 19 ± 1 g) were purchased from Spefox (Beijing) Biotechnology Co., Ltd. Animal Experiment Ethics Number: Safety Evaluation Center Animal (Fu) No. 202410088, Laboratory Animal Use Permit Number: SCXK (Beijing) 2024-0001. Animal experiments were maintained at 20–22°C, 40–60% humidity, and a 12-h light / 12-h dark cycle. Mice had free access to food and water.

[0058] (2) Animal grouping: After 1 week of adaptive feeding, the mice were randomly divided into 8 groups, with 9 mice in each group: normal group (ND group), model group (HFD group), probiotic BLa80 intervention group (BLa80 group, intervened with BLa80 bacterial solution), probiotic BLa80 + lactose-N-neotetraose + brown algae oligosaccharide intervention group (S1 group, intervened with BLa80 bacterial solution containing lactose-N-neotetraose and brown algae oligosaccharide), probiotic BLa80 + lactose-N-neotetraose + fish collagen peptide intervention group (S2 group, intervened with BLa80 bacterial solution containing lactose-N-neotetraose and fish collagen peptide ), probiotic BLa80 + brown algae oligosaccharide + fish collagen peptide intervention group (S3 group, intervened with BLa80 bacterial liquid containing brown algae oligosaccharide and fish collagen peptide), probiotic BLa80 + lactose-N-neotetraose + brown algae oligosaccharide + fish collagen peptide intervention group (S4 group, intervened with BLa80 bacterial liquid containing lactose-N-neotetraose, brown algae oligosaccharide and fish collagen peptide), probiotic BLa80 + 2'-fucosyllactose + chitosan oligosaccharide + bovine collagen peptide intervention group (S5 group, intervened with BLa80 bacterial liquid containing 2'-fucosyllactose, chitosan oligosaccharide and bovine collagen peptide).

[0059] (3) Preparation of test samples:

[0060] (3.1) BLa80 group: 6×10 9 CFU / mL of bacterial suspension;

[0061] (3.2) Group S1: Prepare a suspension of BLa80 bacteria containing lactose-N-neotetraose and brown algal oligosaccharides, where the concentration of BLa80 bacteria is 6×10 9 CFU / mL, of which the concentration of lactose-N-neotetraose was 0.36 g / mL, and the concentration of fucoidan was 0.24 g / mL;

[0062] (3.3) Group S2: Prepare a BLa80 bacterial suspension containing lactose-N-neotetraose and fish collagen peptide, where the concentration of BLa80 bacteria is 6×10 9 CFU / mL, of which the concentration of lactose-N-neotetraose was 0.45 g / mL, and the concentration of fish collagen peptide was 0.15 g / mL;

[0063] (3.4) Group S3: Prepare a suspension of BLa80 bacteria containing brown algal oligosaccharides and fish collagen peptides, where the concentration of BLa80 bacteria is 6×10 9 CFU / mL, of which the concentration of brown algal oligosaccharide was 0.4 g / mL and the concentration of fish collagen peptide was 0.2 g / mL;

[0064] (3.5) Group S4: Prepare a BLa80 bacterial suspension containing lactose-N-neotetraose, brown algal oligosaccharides, and fish collagen peptides, where the concentration of BLa80 bacteria is 6×10 9 CFU / mL, of which the concentration of lactose-N-neotetraose was 0.3 g / mL, the concentration of fucoidan was 0.2 g / mL, and the concentration of fish collagen peptide was 0.1 g / mL;

[0065] (3.6) Group S5: Prepare a BLa80 bacterial suspension containing 2'-fucosyllactose, chitosan oligosaccharide, and bovine collagen peptide, where the concentration of BLa80 bacteria is 6×10 9 CFU / mL, wherein the concentration of 2'-fucosyllactose is 0.5 g / mL, wherein the concentration of chitosan oligosaccharide is 0.5 g / mL, wherein the concentration of bovine collagen peptide is 0.1 g / mL;

[0066] (4) Animal modeling and intervention methods:

[0067] Obesity model mice were established according to the method described in reference (Cheng Kong, Ren yuan Gao, Xue bing Yan, Lin sheng Huang, Huan long Qin, Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet, Nutrition, Volume 60, 2019).

[0068] After successful modeling, mice in each group were intervened for 49 days. The mice in the normal group (ND group) and the model group (HFD group) were gavaged with sterile saline once a day, 0.2 mL each time, for 49 consecutive days; the mice in the other groups were gavaged with BLa80 bacterial suspension or BLa80 bacterial suspension containing prebiotics, once a day, 0.2 mL each time, for 49 consecutive days.

[0069] (5)Indicator analysis:

[0070] (5.1) Monitoring of body weight and obesity index:

[0071] During the experiment, the average body weight and average obesity index of each group of mice were measured and calculated every week (obesity index = (weight of mice in each intervention group - average weight of normal group) / average weight of normal group × 100%). The statistical results are as follows: Figure 1 、 Figure 2 shown.

[0072] The weight growth of mice in each group from week 0 to week 7 is as follows Figure 1 As shown, the weight of the model group mice fed with high-fat diet continued to increase; the weight gain of the mice after intervention with probiotic BLa80 was significantly inhibited, and at the end of the seventh week of treatment, the difference between the model group and the BLa80 intervention group reached a significant level (p<0.05); the mice after intervention with probiotic BLa80 combined with prebiotics had better weight control effect, and the effect of using three prebiotics at the same time was the best.

[0073] Obesity index is a commonly used indicator to judge the obesity standard of mice. It is generally considered that obesity is greater than 20%. The obesity index of mice is continuously monitored during treatment. The results are as follows Figure 2 As shown, compared with the model group mice, the obesity index of obese mice was reduced after intervention with probiotic BLa80; the obesity index of mice intervened with probiotic BLa80 combined with prebiotics was lower, and the effect of using three prebiotics at the same time was the best.

[0074] (5.2) Effects on organ weights in obese mice:

[0075] After the experiment, the scapular brown adipose tissue (BAT), epididymal white adipose tissue (eWAT), inguinal white adipose tissue (iWAT), and liver tissue of each group of mice were sampled and weighed. Figure 3 、 Figure 4 、 Figure 5 and Figure 6 shown.

[0076] The weights of epididymal white fat, inguinal white fat, scapular brown fat, and liver in the model group mice were significantly different from those in the normal group (p<0.05). Compared with the model group, the BLa80 probiotic intervention group significantly reduced epididymal white fat weight (p<0.05), inguinal white fat weight (p<0.05), scapular brown fat weight (p<0.05), and liver weight (p<0.05) in the obese model mice. Compared with the BLa80 probiotic intervention group, the BLa80 combined with prebiotic intervention group further reduced epididymal white fat weight, inguinal white fat weight, scapular brown fat weight, and liver weight in the obese model mice, with the combined use of all three prebiotics having the greatest effect. This suggests that BLa80 intervention can effectively reduce white fat weight in mice, thereby effectively reducing their weight.

[0077] (5.3) Effects on liver biochemical parameters in obese mice:

[0078] After the experiment, the liver tissues of mice in each group were collected. After pre-treatment and grinding of fresh liver, the inflammatory factors and liver metabolic indexes of mice were measured according to the operating procedures of the ELISA kit. Including LPS (lipopolysaccharide), AST (aspartate aminotransferase), ALT (alanine aminotransferase). The test results are as follows: Figure 7 、 Figure 8 and Figure 9 (Different letters in the figure indicate significant differences among the groups, p < 0.05).

[0079] Depend on Figure 7 It can be seen that the LPS concentration in the liver of mice in the model group was significantly higher than that in the normal group. Compared with the model group, the BLa80 group significantly reduced the LPS concentration in the liver of mice (p<0.05), and approached that of the normal group with no significant difference; compared with the BLa80 group, the S1-S5 groups were able to further reduce the LPS concentration in the liver of mice, and the effect of S4-S5 was more obvious.

[0080] Alanine aminotransferase (ALT, commonly known as alanine aminotransferase) and aspartate aminotransferase (AST, commonly known as aspartate aminotransferase) are the most representative transaminases of liver damage. Figure 8 、 Figure 9 The model group showed a significant increase in ALT and AST concentrations compared to the normal group (p < 0.05). The BLa80 group significantly reduced ALT and AST concentrations compared to the model group (p < 0.05), with the ALT reduction effect being particularly pronounced, with no significant difference compared to the normal group (p > 0.05). Compared to the BLa80 group, the S1-S5 groups further reduced ALT and AST concentrations in the mouse liver, with the effect being more pronounced in the S4-S5 groups. This suggests that BLa80 intervention can effectively reduce inflammation in obese mice and protect the liver, reducing damage.

[0081] (5.4) Effects on liver tissue and adipose tissue in obese mice:

[0082] After the experiment, the liver tissue, epididymal white adipose tissue, inguinal white adipose tissue, and scapular brown adipose tissue of the mice in the ND group, HFD group, and BLa80 group were fixed with 4% paraformaldehyde, stained with HE (Sewell Biotechnology Co., Ltd.), and observed and photographed under a 100X microscope. Figure 10-13 shown.

[0083] according to Figure 10 Liver tissue analysis showed that the liver cells of the model group mice had a large amount of fat deformation, and multiple round lipid vacuoles of different sizes appeared in the cytoplasm, and the cytoplasm was loose and lightly stained. The liver tissue structure of the normal group mice was complete, and there were no abnormalities in the liver cells. The situation of the BLa80 group was greatly improved and approached that of the healthy group.

[0084] The enlargement of fat cells is one of the important causes of obesity. Figure 11 、 Figure 12 、 Figure 13 These are epididymal white fat, inguinal white fat, and scapular brown fat. The figure shows that the model group mice had severe lipid accumulation in adipocytes, with chaotic and loose cell arrangement and significantly increased adipocyte diameter. In the normal group, adipocytes were smaller, more densely packed, and more numerous. Compared with the model group, the BLa80 group had relatively smaller adipocyte diameters and more orderly and compact cell arrangement. BLa80 treatment can alleviate adipose tissue hypertrophy in obese mice.

[0085] (5.5) Effects on intestinal flora in obese mice:

[0086] After the experiment, the mice were killed, and their abdomens disinfected and dissected. The cecal contents of the normal, model, and BLa80 groups were collected for microbial diversity analysis. The 16S rDNA V3-V4 hypervariable region of all bacteria in the samples was sequenced on the Mi-Seq Illumina sequencing platform to characterize the intestinal microbiome.

[0087] β-diversity is used to compare the similarity of different samples in terms of species diversity. NMDS is a common analysis method that can reflect the differences and distances of samples. When Stress is less than 0.2, it indicates that the NMDS analysis has a certain degree of reliability. The closer the distance between samples on the coordinate graph, the higher the similarity. The results are as follows Figure 14 As shown in the figure, it can be seen that the intervention of BLa80 effectively improved the intestinal flora of obese model mice and brought it closer to that of the healthy group.

[0088] The relative abundance of different bacterial genera in the intestines of each group of mice is as follows Figure 15 and Figure 16 As shown (different letters in the figure indicate significant differences between groups (p<0.05). Studies have reported that Allobaculum has anti-obesity effects, and a high-fat diet inhibits the growth of Allobaculum strains in the mouse intestine. The abundance of beneficial strains Allobaculum, unclassified_Muribaculaceae, Olsenella, Bifidobacterium, and Lachnoclostridium in the BLa80 group of mice increased significantly (p<0.05), indicating that a 7-week intervention can effectively establish the BLa80 strain in the mouse intestine and promote the increase in the abundance of other beneficial bacteria in the intestine. Bilophila is a conditionally pathogenic bacterium. Usually, a high-fat diet will lead to an increase in the abundance of this strain and promote inflammation in the body. Oral administration of the BLa80 strain can significantly reduce the abundance of the harmful intestinal strain Bilophila (p<0.05), thereby effectively improving lipid metabolism disorders in obese mice and regulating the health of the body.

[0089] The applicant declares that the present invention is illustrated by the above-described embodiments, but the present invention is not limited to the above-described embodiments. This does not mean that the present invention must rely on the above-described embodiments in order to be implemented. Those skilled in the art should understand that any improvements to the present invention, equivalent replacements for raw materials in the present invention, additions of auxiliary ingredients, and selection of specific methods, etc., fall within the scope of protection and disclosure of the present invention.

[0090] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the scope of protection of the present invention.

[0091] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any appropriate manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. Application of Bifidobacterium animalis subspecies lactis BLa80 in the preparation of a preparation for alleviating obesity; The Bifidobacterium animalis subsp. lactis BLa80 is a strain of Bifidobacterium animalis subsp. lactis BLa80 with a preservation number of CGMCC No. 22547.

2. The use according to claim 1, characterized in that The number of viable bacteria in the preparation is not less than 1×10 8 CFU / mL or 1×10 8 CFU / g.

3. The use according to claim 1, characterized in that The dosage forms of the preparation include solution, powder, tablet or capsule.

4. The use according to claim 3, characterized in that The preparation further contains excipients; the excipients include any one or a combination of at least two of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers.

5. The use according to claim 1, characterized in that The preparation further contains prebiotics, which include human milk oligosaccharides, seaweed oligosaccharides and collagen peptides; Preferably, the mass ratio of human milk oligosaccharides, seaweed oligosaccharides and collagen peptides is (2-5):(2-5):

1.

6. The use according to claim 5, characterized in that The human milk oligosaccharide is selected from lactose-N-neotetraose and / or 2'-fucosyllactose, preferably a combination of lactose-N-neotetraose and 2'-fucosyllactose; Preferably, the seaweed oligosaccharide is selected from brown algae oligosaccharide and / or chitosan oligosaccharide; Preferably, the collagen peptide is selected from bovine collagen peptide and / or fish collagen peptide.

7. A probiotic composition for alleviating obesity, characterized in that: The probiotic composition comprises probiotics and prebiotics; the probiotics are Bifidobacterium animalis subspecies lactis BLa80, and the prebiotics comprise human milk oligosaccharides, seaweed oligosaccharides and collagen peptides; The Bifidobacterium animalis subsp. lactis BLa80 is a strain of Bifidobacterium animalis subsp. lactis BLa80 with a preservation number of CGMCC No. 22547.

8. The probiotic composition according to claim 7, characterized in that The ratio of probiotics to prebiotics is not less than 1×10 7 CFU.

9. The probiotic composition according to claim 7, characterized in that The mass ratio of human milk oligosaccharides, seaweed oligosaccharides and collagen peptides is (2-5):(2-5):1; Preferably, the human milk oligosaccharide is selected from lactose-N-neotetraose and / or 2'-fucosyllactose; Preferably, the seaweed oligosaccharide is selected from brown algae oligosaccharide and / or chitosan oligosaccharide; Preferably, the collagen peptide is selected from bovine collagen peptide and / or fish collagen peptide.

10. Use of the probiotic composition according to any one of claims 7 to 9 in preparing a product having any one or at least two of the following effects: 1) Reduce obesity index; 2) Improve fat accumulation caused by obesity; 3) Liver damage caused by obesity; 4) Inflammation in the body caused by obesity; 5) Improve the intestinal flora structure of obese individuals, increase the abundance of beneficial intestinal flora, and reduce the abundance of opportunistic pathogens.

Images